Clinical and Molecular Analysis of 49 Patients With X-linked Agammaglobulinemia From A Single Center in Argentina
Argentina has a large number of patients with definite diagnosis of X-linked agammaglobulinemia reported in the Latin-American registry. Forty-nine of them were seen in our referral pediatric hospital, between 1987 and 2005.
Results and Discussion
A retrospective study of clinical, laboratory, and molecular data showed that respiratory tract infections were the most frequent initial clinical presentation and the most common among all manifestations prior to diagnosis (69%). Up to diagnosis, we found a high frequency of severe infections (sepsis, 14% and meningitis, 16%) and a high proportion of patients with chronic lung disease. During follow-up, the development of chronic lung disease was significantly related with age at diagnosis and inappropriate treatment.
Although molecular diagnosis has been available in our center for the past 10 years, there is no doubt that awareness for early recognition of immunodeficiency should be improved through broader and more comprehensive education programs emphasizing characteristics of patients with immunodeficiencies.
KeywordsX-linked agammaglobulinemia intravenous immunoglobulin chronic lung disease Bruton tyrosine kinase gene
- 2.Noordzij JG, de Bruin-Versteeg S, Comans-Bitter WM, Hartwig NG, Hendriks RW, de Groot R, et al. Composition of precursor B-cell compartment in bone marrow from patients with X-linked agammaglobulinemia compared with healthy children. Pediatr Res 2002;51:159–68. doi: 10.1203/00006450-200202000-00007.PubMedCrossRefGoogle Scholar
- 3.Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, Sparkers RS, Kubagawa H, Mohandas T, Quan S, Belmont JW, Cooper MD, Conley ME, Witte ON. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993;72:279–90. doi: 10.1016/0092-8674(93)90667-F.PubMedCrossRefGoogle Scholar
- 6.Quartier P, Debré M, De Blic J, de Sauverzac R, Sayegh N, Jabado N, et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr 1999;134:589–96. doi: 10.1016/S0022-3476(99)70246-5.PubMedCrossRefGoogle Scholar
- 8.Plebani A, Soresina A, Rondelli R, Amato GM, Azzari C, Cardinale F, et al. Italian Pediatric Group for XLA-AIEOP. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol 2002;104:221–30. doi: 10.1006/clim.2002.5241.PubMedCrossRefGoogle Scholar
- 12.Leiva LE, Zelazco M, Oleastro M, Carneiro-Sampaio M, Condino-Neto A, Costa-Carvalho BT, Latin American Group for Primary Immunodeficiency Diseases, et al. Primary immunodeficiency diseases in Latin America: the second report of the LAGID registry. J Clin Immunol 2007;27:101–8. doi: 10.1007/s10875-006-9052-0.PubMedCrossRefGoogle Scholar
- 16.Lindvall JM, Blomberg KE, Väliaho J, Vargas L, Heinonen JE, Berglöf A, et al. Bruton’s tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol Rev 2005;203:200–15. doi: 10.1111/j.0105-2896.2005.00225.x.PubMedCrossRefGoogle Scholar